Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

Inclusion Criteria: * Male or female 18 - 40 years of age. * Documented history of being homozygous for ΔF508 CFTR genotype. * Able to perform spirometry maneuvers, and have a forced expiratory volume at 1 second (FEV1) greater than or equal to 30% of predicted normal for age, gender, and height (Knudson standards) at screening. * Oxygen saturation (as measured by pulse oximetry) \> 90% on room air at screening. * Clinically stable with no evidence of acute upper or lower respiratory tract infection. * Non-smoker for at least 6 months prior to screening. * Able to understand and sign a written informed consent and comply with the requirements of the study. Exclusion Criteria: * Diagnosis of acute pulmonary exacerbation (PE) requiring antibiotic intervention within 4 weeks prior to screening. * Patient reported history of viral upper respiratory tract infection within 2 weeks prior to screening. * History of major complications of lung disease (including recent massive hemoptysis or pneumothorax) within two months prior to screening Visit. * Acute nosebleeds within 14 days prior to screening. * Nasal surgery within 4 weeks prior to screening. * Begun use of nasal antibiotics, nasal steroids, nasal cromolyn, nasal atrovent, nasal phenylephrine, or oxymetazoline within 14 days prior to screening. * Chest x-ray at screening or within 3 months of screening with abnormalities suggesting clinically significant active pulmonary disease other than cystic fibrosis, and/or new CF-specific changes including atelectasis, small pneumothoraces, or pneumonia. * EKG at screening which shows clinically significant abnormality including prolonged QTc, bundle branch block, rhythm other than sinus, evidence of ischemic heart disease.